Physician profile
Steven B Eiden
NPI 1457342685
$258,503.75
in general payments reported to CMS, 2019-2025
31 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108K · 2020: $95K · 2021: $1,875 · 2022: $5,123 · 2023: $43K · 2024: $5,825 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Honoraria: $5,000 · Food and Beverage: $2,327 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,700.00 |
| Honoraria | $5,000.00 |
| Food and Beverage | $2,326.51 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oculus, INC. | $182,200.00 | 2019-2024 | Pentacam |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $30,247.06 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $16,395.28 | 2022-2024 | Zenlens, Miebo, Xiidra |
| Sight Sciences, INC. | $16,029.31 | 2019-2020 | |
| Alcon Vision LLC | $6,519.09 | 2019-2024 | Simbrinza, Rocklatan, Rhopressa |
| Sun Pharmaceutical Industries INC. | $2,117.11 | 2019-2024 | Cequa |
| Glaukos Corporation | $1,324.66 | 2021-2023 | Kxl1b-Ce-Marked Kxlsystem, Kxl System (Not Refurbished) |
| Kala Pharmaceuticals, INC. | $718.05 | 2021 | |
| Lkc Technologies, INC. | $457.54 | 2023 | |
| Novartis Pharmaceuticals Corporation | $392.00 | 2019-2023 | |
| Oyster Point Pharma, INC. | $281.15 | 2022-2024 | Tyrvaya, Ryzumvi |
| Shire North American Group INC | $234.51 | 2019 | |
| Coopervision INC. | $211.77 | 2021-2023 | Myday Contact Lens, Onefit Contact Lens, Paragon Crt |
| Visioneering Technologies, INC. | $192.26 | 2019-2020 | |
| Optos, INC. | $181.81 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $174.38 | 2019-2024 | |
| Abbvie INC. | $114.86 | 2023-2024 | |
| Thea Pharma INC. | $114.68 | 2023 | |
| Lombart Brothers, INC. | $106.35 | 2019 | |
| Notal Vision, INC. | $92.33 | 2022 | |
| Maculogix, INC. | $82.52 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $73.48 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $47.37 | 2021 | |
| Allergan, INC. | $45.50 | 2021-2022 | |
| Quidel Corporation | $28.86 | 2020 | |
| Eyevance Pharmaceuticals LLC | $24.41 | 2020-2021 | |
| Harrow Eye, LLC | $24.16 | 2024 | Vevye |
| Carl Zeiss Meditec, INC. | $20.81 | 2019 | |
| Alcon Research LLC | $18.11 | 2019 | |
| Dompe US, INC. | $17.91 | 2022 | |
| Spark Therapeutics, INC. | $16.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Eiden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.